Clinical Trials on Mismatch Repair Deficient (dMMR)

Total 381 results

The Hospital for Sick Children
Bristol-Myers Squibb

Terminated

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Refractory or Recurrent Hypermutated Malignancies | Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients

United States, France, Canada, Australia, Israel
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Evaluation of the Reliability of the Determination of MisMatch Repair Deficiency Status by Endoscopic Biopsies in Oesophagus and Gastric Adenocarcinoma. (BIOPSYGAST MMR)

Gastro-oesophageal Adenocarcinoma
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142)

Microsatellite Stable Colorectal Cancer | Mismatch Repair Proficient Colorectal Cancer | Microsatellite Unstable Colorectal Cancer | Mismatch Repair Deficient Colorectal Cancer

United States, Australia, Belgium, Canada, Ireland, Italy, Spain, France
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Mismatch Repair Deficiency | Adenocarcinoma of Esophagogastric Junction

China
Apollomics (Australia) Pty. Ltd.
Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...

Completed

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Solid Tumor | Microsatellite Instability | Mismatch Repair Deficiency | Cancer of Unknown Primary Site

Australia
Peking Union Medical College Hospital

Recruiting

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer (NITDC)

Colon Cancer | Immunotherapy | Mismatch Repair Deficiency

China
Yu jiren

Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Proficient Mismatch Repair

China
The Netherlands Cancer Institute
Agenus Inc.

Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

Resectable MMR-deficient Solid Tumors | Resectable MMR-proficient Solid Tumors

Netherlands
National Center for Tumor Diseases, Heidelberg
AstraZeneca; German Cancer Research Center; PharmaMar

Completed

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603)

Cancers With DNA Repair-Deficiency

Germany
VA Office of Research and Development
Merck Sharp & Dohme LLC

Recruiting

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)

Metastatic Castration Resistant Prostate Cancer

United States
University Health Network, Toronto
AstraZeneca

Active, not recruiting

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)

Pancreatic Adenocarcinoma | Leiomyosarcoma | Mismatch Repair Proficient Colorectal Cancer

Canada
University of Colorado, Denver
National Cancer Institute (NCI); Cancer League of Colorado

Withdrawn

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Colorectal Cancer | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Sun Yat-sen University
The Second Affiliated Hospital of Kunming Medical University

Completed

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Colorectal Cancer Metastatic | Microsatellite Instability High | Mismatch Repair Deficiency

China
University of British Columbia

Unknown

Melatonin and DNA Damage Study

Oxidative Stress | Sleep Quality | DNA Damage Repair Deficiency
BeiGene

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

China, United States, Australia, Puerto Rico
Idience Co., Ltd.

Active, not recruiting

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) (VASTUS)

Solid Tumors | Homologous Recombination Deficiency | Homologous Recombination Repair Gene Mutation

Korea, Republic of
WellSpan Health

Active, not recruiting

Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome

Endometrial Hyperplasia | Lynch Syndrome | Endometrial Cancer | Microsatellite Instability | Mismatch Repair Deficiency

United States
Rottapharm Biotech
Agenus Inc.

Active, not recruiting

A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Solid Tumor | Metastatic Microsatellite-stable Colorectal Cancer | Mismatch Repair Protein Proficient | Refractory Metastatic Colorectal Cancer

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

High-Frequency Microsatellite Instability | Mismatch Repair Gene Mutation | Mutation-Negative Lynch Syndrome | Mutation-Positive Lynch Syndrome

United States
Incyte Corporation

Recruiting

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Melanoma | Hepatocellular Carcinoma (HCC) | Renal Cell Carcinoma (RCC) | Colorectal Carcinoma (CRC) | Microsatellite Instability - High (MSI-H) | Mismatch Repair Deficient (dMMR)

United States, Canada, South Africa, Mexico
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
Zhejiang Cancer Hospital

Recruiting

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | Microsatellite Stable | Mismatch Repair-proficient

China
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Assistance Publique - Hôpitaux de Paris

Recruiting

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (ARTEGENE)

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

France
Medical University Innsbruck

Unknown

Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation (CMMRD in NF1)

Neurofibromatosis Type 1
National Cancer Institute (NCI)

Completed

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Virginia Commonwealth University

Recruiting

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Endometrial Cancer | Recurrent Endometrial Cancer | Mismatch Repair-Proficient

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome

Nijmegen Breakage Syndrome

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

Nijmegen Breakage Syndrome

Russian Federation
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Gastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditions

United States
Asan Medical Center

Recruiting

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM)

Biliary Tract Cancer | DNA Damage Repair Deficiency

Korea, Republic of
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System; Prostate Cancer Foundation

Terminated

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
National Institute of Allergy and Infectious Diseases...

Enrolling by invitation

Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus

Severe Combined Immune Deficiency (SCID)

United States
Udai Kammula

Recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Sarcoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Neuroendocrine Tumors | Mesothelioma | Merkel Cell Carcinoma | Microsatellite Instability | Squamous Cell Cancer | Mismatch Repair Deficiency

United States
Chiesi Farmaceutici S.p.A.

Completed

Registry Study of Revcovi Treatment in Patients With ADA-SCID

Severe Combined Immunodeficiency | Adenosine Deaminase Deficiency

United States
Emory University

Completed

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

Severe Combined Immunodeficiency | T-Cell Immune Deficiency Diseases

United States
University of California, Los Angeles

Recruiting

Autologous Mobilized Peripheral Blood CD34+ Hematopoietic Stem and Progenitor Cells (HSPC) Transduced With the Elongation Factor Alpha Short Promoter (EFS) - Adenosine Deaminase (ADA) Gene (EFS-ADA) Lentiviral Vector for Adenosine Deaminase Severe Combined Immune Deficiency (ADA SCID)

Adenosine Deaminase Severe Combined Immune Deficiency

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
Leadiant Biosciences, Inc.

Completed

EZN-2279 in Patients With ADA-SCID

Severe Combined Immunodeficiency | ADA-SCID | Adenosine Deaminase Deficiency

United States
Great Ormond Street Hospital for Children NHS Foundation...

Completed

Gene Therapy ADA Deficiency

Adenosine Deaminase Deficiency

United Kingdom
Fondazione Telethon

Completed

Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)

Severe Combined Immunodeficiency Due to ADA Deficiency

Italy
University of California, Los Angeles
Great Ormond Street Hospital for Children NHS Foundation Trust

Enrolling by invitation

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

Adenosine Deaminase Deficiency | Severe Combined Immunodeficiency (SCID)

United States, United Kingdom
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Horizon...

Recruiting

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID (RAG1-SCID)

Severe Combined Immunodeficiency Due to RAG1 Deficiency

Spain, Netherlands, Italy, Poland, Australia, Turkey, United Kingdom
University of California, Los Angeles
Orchard Therapeutics; California Institute for Regenerative Medicine (CIRM)

Completed

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Severe Combined Immunodeficiency Due to ADA Deficiency

United States
Great Ormond Street Hospital for Children NHS Foundation...
Orchard Therapeutics

Completed

Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency

Adenosine Deaminase Deficiency | Severe Combined Immunodeficiencies (SCID)

United Kingdom

Clinical Trials on Mismatch Repair Deficient (dMMR)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations